Redefining Care Through Kidney Cancer Research

At University Hospitals Seidman Cancer Center, advancements in kidney cancer research are expanding the boundaries of clinical possibilities, offering patients innovative diagnostic methods and treatments that go beyond standard care—many of which are not yet available at other medical centers.

Research and innovation enable our physicians to provide patients with the most state-of-the-art kidney cancer therapies and treatment approaches in a fast-evolving field. We are breaking new ground with different immune therapies and targeted treatments designed to maximize the therapeutic benefits for patients and their specific type of cancer, while minimizing the effects of treatment on healthy tissue.

Throughout University Hospitals, clinical trials and research studies continually drive us forward, making it possible to provide patients with hope and new life-extending options that few medical centers yet offer. The novel drug targets and cellular mechanisms we explore and develop reframe the course of medicine.

Our Experts Help Determine the Next Generation of Kidney Cancer Care

Our extensive cancer team is helping to determine the next generation of innovations in kidney cancer care through multiple efforts. UH Seidman Cancer Center physician scientists participate in the National Comprehensive Cancer Network guidelines for management of Renal Cell Carcinoma.

Our UH genitourinary medical oncology experts serve as committee member for the Society for Immunotherapy for Cancer Guidelines in Immunotherapy for Renal Cell Carcinoma. Additionally, medical oncology experts are part of national consortium to explore putative biomarkers to optimize and personalize treatment to patients with advanced renal cell carcinoma.

Internationally recognized radiation oncology experts at UH Seidman Cancer Center are on the Renal Task Force for the National Cancer Institute to evaluate national and international research opportunities to improve care. In addition, we participate in the International Radiation Oncology Consortium for Kidney (IROCK) to gather data for stereotactic radiosurgery for kidney cancer to continue to investigate opportunities to enhance outcomes.